One of the first major hurdles in understanding bispecific antibody drugs is recognizing that the single term “bispecific antibody drugs” actually includes fundamentally different molecular design concepts. In A1, we described bispecific antibody drugs as an antibody design technology that creates new pharmacological functions by combining two conditions. However, in order to make that function work as a real medicine, it is not enough to choose the targets. It is equally critical to decide what molecular format will carry that design.
This is because, in bispecific antibody drugs, structure itself is directly linked to efficacy, safety, half-life, tissue penetration, manufacturability, and dosing convenience. Structure is important in conventional monoclonal antibodies as well, but in bispecific antibody drugs it becomes even more decisive. How two binding functions are combined within one molecule, how large the molecule is made, whether it includes an Fc region, what valency it has, and how asymmetry is controlled can all dramatically change the nature of the final drug, even when the same target pair is used.
In this B1 article, we will compare the major structural designs used in bispecific antibody drugs and organize what each of them means therapeutically. We will begin with broad categories such as IgG-like formats, non-IgG formats, and fusion-protein formats, and then examine why differences in valency, binding arrangement, Fc presence, and molecular size are not merely differences in appearance but differences in pharmacology. The important goal is not to decide which format is universally superior, but to understand which design is better suited for which purpose.
Why is structural design so important?
In bispecific antibody drugs, structural design is not just a difference in “how the molecule is made.” Structure determines how long the drug stays in the body, how easily it reaches certain tissues, how strongly it recruits immune cells, how likely it is to cause toxicity, and even whether it can be manufactured in a stable and reproducible way. In other words, structure is not an engineering detail outside efficacy. It is part of efficacy itself.
Because bispecific antibody drugs must incorporate two different specificities into one molecule, they have greater structural design freedom than conventional antibodies, but they also face more constraints. For example, giving a molecule two arms may sound simple in concept, but in practice the correct chains must pair with one another, and unwanted combinations or heterogeneous products can easily arise. Also, when strong functions such as T-cell activation are being pursued, even subtle structural differences can significantly change both activity and toxicity.
For this reason, in bispecific antibody drug design, “what the molecule binds to” is only half the question. “In what structural form that binding is implemented” is equally important. For one target pair, a small format that enables tight bridging may be advantageous. For another indication, an IgG-like stable structure may be needed to extend half-life, maintain dosing intervals, and improve safety. In that sense, structural design in bispecific antibody drugs is a translational process that connects target biology with clinical requirements.
Major structural classes of bispecific antibody drugs
The structural landscape of bispecific antibody drugs is extremely diverse, but at the beginner stage it is useful to divide it broadly into three categories: IgG-like formats, non-IgG formats, and fusion-protein formats. This three-part classification does not cover every possible design in a strict sense, but it is very useful for organizing the relationship between structure and pharmacology.
1. IgG-like formats
IgG-like formats are designs that preserve a framework similar to a conventional IgG antibody while incorporating bispecificity. Structurally, they resemble standard antibodies to a considerable extent, often include an Fc region, and tend to have advantages in half-life, structural stability, and accumulated manufacturing and purification experience. In recent bispecific antibody drug development, IgG-like formats have taken on a very important role.
The major advantage of IgG-like formats is that they remain relatively close to an already established antibody therapeutic platform. Because they contain an Fc region, FcRn-mediated recycling can often be leveraged to prolong half-life. This is important for reducing dosing frequency and improving patient convenience. In addition, the molecule itself is often more stable, and the manufacturing process tends to be more predictable, which is advantageous from both clinical development and commercialization perspectives.
At the same time, IgG-like formats are often larger molecules, and they are not always optimal in terms of tissue penetration or in achieving the ideal intercellular distance for certain biological effects. Also, when two different heavy chains and light chains must be paired correctly, sophisticated engineering is needed to avoid mispairing. In other words, IgG-like formats are stable and practical, but they may come with the complexity of structural control and limitations associated with larger molecular size.
2. Non-IgG formats
Non-IgG formats do not adopt the full IgG structure and instead use smaller, more flexible molecular architectures. These include designs based on scFv and related antibody fragments, and they are frequently seen in T-cell engager approaches. Such formats may enable very close bridging between cells and can produce highly potent functional activity.
The major advantage of non-IgG formats is their small size. Because the molecule is smaller, it may be easier to control intercellular distance, which can be highly beneficial when efficient contact between T cells and tumor cells is required. They also tend to offer a high degree of design flexibility and make it easier to build compact functional modules tailored to a specific purpose.
However, that same small size can also be a disadvantage. If the molecule lacks an Fc region, or otherwise lacks the long half-life characteristic of IgG-like molecules, clearance from the body may become rapid, and continuous infusion or frequent dosing may be required to achieve sustained exposure. In addition, there may be challenges in structural stability or handling during manufacturing. As a result, strong activity may come at the cost of more difficult dosing strategies and formulation design.
3. Fusion-protein formats
Fusion-protein formats are designs in which antibody fragments, receptor-binding domains, or other functional units are linked together with additional protein domains. These designs are not necessarily constrained by the traditional shape of an antibody, and are closer in spirit to building pharmacological action by combining the functional units that are needed. In some cases, it may be more appropriate to view them not simply as antibody engineering, but as a broader form of molecular engineering.
The advantage of fusion-protein formats is their high degree of functional design freedom. They can be well suited to combining localization, activation conditions, and multifunctionality at the molecular level, and may fit especially well with next-generation concepts such as conditionally activated or locally acting molecules. Depending on the target biology and desired mechanism of action, they may also be more rational than maintaining a full antibody framework.
At the same time, fusion-protein formats generally bring greater design complexity and require careful evaluation of stability, immunogenicity, manufacturing reproducibility, and pharmacokinetic predictability. The more structural freedom a design has, the more easily small design changes can lead to unexpected behavior. For that reason, fusion-protein formats offer high potential, but they also tend to come with greater development difficulty.
What does the presence or absence of an Fc region mean?
One of the most important structural branching points in bispecific antibody drug design is whether the molecule contains an Fc region. The Fc region corresponds to the lower half of an IgG antibody and has many roles, including half-life extension through interaction with FcRn, participation in immune effector functions, and contributions to molecular stability.
Designs with an Fc region generally have the advantage of a longer half-life and therefore allow less frequent dosing. This is highly important in the context of chronic administration and outpatient treatment settings. In addition, because manufacturing and purification platforms are relatively well established, development can become more predictable.
However, having an Fc region is not always beneficial. In bispecific antibody drugs designed to strongly activate T cells, unwanted Fc-dependent effector functions may contribute to adverse effects, making it preferable either to silence the Fc or to remove it entirely. Also, the larger molecular size associated with an Fc-bearing design can sometimes be disadvantageous for reaching the target site or optimizing intercellular distance.
So the presence or absence of an Fc region is not just a minor structural detail. It is a design decision that can simultaneously reshape half-life, safety, mode of activity, and dosing strategy. There is no universal answer as to which is better. The optimal choice depends on the targets, the mechanism of action, and how the drug is intended to be used clinically.
Why are valency and binding arrangement important?
In bispecific antibody drugs, valency—meaning how many binding sites are assigned to each target—is also a critical design parameter. Some designs are symmetric, with one binding site for one target and one for the other, while others are asymmetric, such as having two binding sites for the tumor antigen and one for the immune-cell target. These choices affect effective affinity, cell-surface retention, selectivity, and activation threshold.
For example, providing multivalency toward the tumor antigen may increase avidity on the tumor surface and improve discrimination from normal cells that express the same antigen at lower levels. On the other hand, giving excessively high affinity or multivalency toward the immune-cell target—especially a strong activator such as CD3—may lead to excessive immune activation and toxicity. As a result, how much strength and valency are assigned to each side becomes a very delicate optimization problem.
Spatial arrangement of the binding sites is also important. The distance, angle, and flexibility with which the two targets are bridged can influence the efficiency of immune synapse formation or receptor clustering. At first glance, this may seem like a fine detail of molecular design, but in reality it is one of the core determinants of efficacy and toxicity.
The relationship between molecular size and tissue penetration
Molecular size is another major functional determinant in bispecific antibody drugs. In general, smaller molecules tend to have better tissue penetration and easier access between cells. In solid tumors in particular, problems such as stromal barriers, vascular permeability, and local concentration gradients may make the advantages of smaller molecules more visible.
At the same time, smaller molecules are more likely to undergo rapid renal clearance, which shortens their residence time in the body. As a result, continuous infusion or frequent dosing may be needed to maintain adequate exposure. Larger molecules, by contrast, may have more favorable half-life properties, but may be disadvantaged in deep tissue penetration or in achieving uniform local distribution.
For this reason, optimizing molecular size cannot be thought of only in terms of “how easily the molecule reaches the target.” It must also be considered in terms of the trade-off with “how long the molecule remains in the body.” A format that is small and highly active may work well in hematologic malignancies, but a different optimum may exist for solid tumors or for indications that require chronic dosing. Structural design is, in part, the process of resolving this trade-off differently for each indication.
How structural design directly affects therapeutic effects
As discussed so far, structural design influences every aspect of pharmacology, but in the end its impact becomes visible as therapeutic effect. For example, in T-cell engager approaches, smaller structures that allow tight intercellular spacing may produce stronger killing activity, but at the cost of shorter half-life and more difficult toxicity management. Conversely, a stable IgG-like structure may improve dosing convenience and durability of exposure, while yielding a different local density or kinetic profile of activity.
Also, in designs intended to enhance tumor selectivity, valency, binding sequence, flexibility, and localization mechanisms all influence the balance between activity in tumors and unwanted effects in normal tissues. In other words, even if two drugs target the same pair of molecules A × B, different molecular architectures can produce very different efficacy and safety profiles in the clinic. This is where both the difficulty and the fascination of bispecific antibody drug development become concentrated.
Even more importantly, the structure that maximizes therapeutic effect is not determined by any single performance metric. Strong activity alone is not enough. A “good structure” must also be realistically administrable to patients, manufacturable with reproducibility, compatible with combination therapy, and manageable from a toxicity perspective. Structural optimization in bispecific antibody drugs is therefore not merely molecular design, but integrated design directed toward real clinical implementation.
Which structure is the best?
The natural question that follows is: which structure is ultimately the best? But the most honest answer is that there is no universally best format. This is because the structural optimum in a bispecific antibody drug depends on the biology of the target, the disease area, the required pharmacology, the route and schedule of dosing, the acceptable safety profile, and the requirements for commercialization.
For example, if the goal is rapid and strong T-cell redirection in hematologic malignancies, a small and highly active non-IgG format may make sense. On the other hand, if the goal is repeated outpatient dosing with secure half-life and stable handling, an IgG-like format may be more advantageous. If one wants to improve tumor selectivity or localized activity in solid tumors, still another design logic may be required.
So the quality of a structure cannot be judged in isolation. It is determined by what one is trying to achieve. Without this perspective, it becomes easy to misinterpret the success of one format and try to apply the same design to every target. What truly matters in bispecific antibody drug structural design is not following whichever format is fashionable, but choosing the molecular architecture that is most rational for the target biology and the intended indication.
How this connects to the rest of the series
The central message to carry forward from B1 is that, in bispecific antibody drugs, structure determines pharmacology, and pharmacology determines clinical value. The idea introduced in A1—combining two conditions to create a new pharmacological function—becomes concrete at the molecular level for the first time in B1. Even within the same label of “bispecific antibody drug,” differences in structural design can make two molecules behave like entirely different medicines.
In the next article, A2, we will return to a more accessible level and organize how these structural differences ultimately appear as differences in mechanism of action. By looking at differences such as T-cell redirection, dual signal control, and localized activation, and understanding how those mechanisms translate into therapeutic meaning, the relationship between structure and function should become even more three-dimensional.
Conclusion
Structural design in bispecific antibody drugs is not a matter of visual variation. It is a core determinant of efficacy, safety, half-life, tissue penetration, and manufacturability. The main categories—IgG-like formats, non-IgG formats, and fusion-protein formats—each carry distinct advantages and constraints, and differences in Fc presence, valency, binding arrangement, and molecular size directly become differences in therapeutic character.
The important point is not to decide which format is generally superior. What matters is selecting the structure that is most rational for the intended target, disease setting, and desired mode of action. Development of bispecific antibody drugs can be understood as the process of solving a complex translational problem between target biology and clinical requirements through molecular architecture.
In the next article, A2, we will examine how these differences in molecular design ultimately appear as differences in mechanisms of action. We will deepen the discussion one step further, moving from structure to function.
Related Articles
Comments